Thrombotic Thrombocytopenic Purpura (TTP) Market Report 2026

Thrombotic Thrombocytopenic Purpura (TTP) Market Overview

• Thrombotic Thrombocytopenic Purpura (TTP) market size has reached to $1.04 billion in 2025 • Expected to grow to $1.29 billion in 2030 at a compound annual growth rate (CAGR) of 4.3% • Growth Driver: Rising Prevalence Of Cardiovascular Diseases Driving The Market Growth • Market Trend: Innovative Therapies With Advancement Of Recombinant Enzyme Replacement Therapy • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Thrombotic Thrombocytopenic Purpura (TTP) Market?

Thrombotic thrombocytopenic purpura (TTP) is a rare, life-threatening blood disorder characterized by the formation of small blood clots (thrombi) in the blood vessels throughout the body. These clots can block blood flow to various organs, leading to potential organ damage. Thrombotic thrombocytopenic purpura (TTP) is treated primarily with plasmapheresis to remove harmful antibodies and replace the deficient ADAMTS13 enzyme. The main types of thrombotic thrombocytopenic purpura (TTP) are inherited thrombotic thrombocytopenic purpura (TTP) and acquired thrombotic thrombocytopenic purpura (TTP). Inherited TTP is a rare genetic disorder caused by mutations in the ADAMTS13 gene, leading to defective von Willebrand factor breakdown and recurrent blood clotting episodes. The various treatment options include plasma exchange, corticosteroids, rituximab, caplacizumab, and other therapies. These are used by various end-users, including hospitals, specialty centers, and other healthcare facilities.

What Is The Thrombotic Thrombocytopenic Purpura (TTP) Market Growth Forecast?

The thrombotic thrombocytopenic purpura (ttp) market size is expected to see steady growth in the next few years. It will grow to $1.29 billion in 2030 at a compound annual growth rate (CAGR) of 4.3%. The growth in the forecast period can be attributed to increasing adoption of caplacizumab therapy, rising investments in rare disease research, expansion of genetic testing for adamtS13 deficiency, growing focus on early relapse prevention, increasing establishment of specialized ttp treatment centers. Major trends in the forecast period include increasing use of targeted biologic therapies, rising adoption of plasma exchange innovations, growing focus on rapid diagnostic protocols, expansion of specialized treatment centers, enhanced patient monitoring technologies.

Global Thrombotic Thrombocytopenic Purpura (TTP) Market Segmentation

1) By Type: Inherited Thrombotic Thrombocytopenic Purpura (TTP), Acquired Thrombotic Thrombocytopenic Purpura (TTP) 2) By Treatment: Plasma Exchange, Corticosteroids, Rituximab, Caplacizumab, Other Treatment Types 3) By End-Users: Hospitals, Speciality Centres, Other End Users Subsegments: 1) By Inherited Thrombotic Thrombocytopenic Purpura (TTP): Congenital ADAMTS13 Deficiency, Upshaw-Schulman Syndrome 2) By Acquired Thrombotic Thrombocytopenic Purpura (TTP): Immune-Mediated TTP, Secondary TTP

What Are The Drivers Of The Thrombotic Thrombocytopenic Purpura (TTP) Market?

The rising prevalence of cardiovascular diseases is expected to propel the growth of the thrombotic thrombocytopenic purpura (TTP) market going forward. Cardiovascular diseases refer to a group of disorders affecting the heart and blood vessels, including conditions such as coronary artery disease, heart failure, and stroke. The rising prevalence of cardiovascular diseases is attributed to factors such as aging populations, unhealthy diets, physical inactivity, obesity, smoking, excessive alcohol consumption, and increasing stress levels. Thrombotic thrombocytopenic purpura (TTP) contributes to cardiovascular diseases by causing widespread microvascular thrombosis, endothelial dysfunction, and systemic inflammation, which increase the risk of hypertension, myocardial infarction, and other cardiovascular complications. For instance, in January 2024, according to the American Heart Association, a US-based non-profit organization, the age-adjusted death rate from cardiovascular disease increased to 233.3 per 100,000 in 2024, an increase of 4.0% from 224.4 per 100,000 compared to 2023. Therefore, the rising prevalence of cardiovascular diseases is driving the growth of the thrombotic thrombocytopenic purpura (TTP) industry. The rise in healthcare spending is expected to propel the growth of the thrombotic thrombocytopenic purpura (TTP) market going forward. Healthcare spending refers to the total expenditure on health services and products, including medical care, hospital services, preventive care, medications, research, infrastructure, and administrative costs, aimed at maintaining or improving the health and well-being of individuals and populations. Healthcare spending is attributed to aging population, advancements in medical technology, rising prevalence of chronic diseases, and increased demand for healthcare services. Healthcare expenditure supports thrombotic thrombocytopenic purpura (TTP) by enabling access to advanced diagnostics, life-saving treatments such as plasma exchange and immunosuppressive therapy, continuous patient monitoring, and ongoing research into innovative therapies, ultimately enhancing patient outcomes and reducing complications. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, between 2022 and 2023, healthcare spending in the UK increased by 5.6% compared with growth of 0.9% in 2022. The UK healthcare expenditure in UK healthcare expenditure was around $317.63 billion (£292 billion) in 2023. Therefore, rise in healthcare spending is driving the growth of the thrombotic thrombocytopenic purpura (TTP) industry.

Key Players In The Global Thrombotic Thrombocytopenic Purpura (TTP) Market

Major companies operating in the thrombotic thrombocytopenic purpura (ttp) market are Pfizer Inc., Takeda Pharmaceutical Company, Sanofi S.A., Baxter International Inc., Octapharma AG, Omeros Corporation, Rigel Pharmaceuticals Inc., Biocryst Pharmaceuticals Inc., TargED Biopharmaceuticals B.V., Carelon Research, Archemix Corp., Eisai Inc., Shionogi & Co. Ltd., Global Blood Therapeutics, Beijing InnoCare Pharma, Gilead Sciences, Merck & Co. Inc., AstraZeneca, Janssen Pharmaceutical Companies, F Hoffmann‑La Roche Ltd, CSL Behring

Global Thrombotic Thrombocytopenic Purpura (TTP) Market Trends and Insights

Major companies operating in the thrombotic thrombocytopenic purpura (TTP) market are focusing on development of innovative therapies such as recombinant enzyme replacement therapy to improve treatment efficacy and patient outcomes. Recombinant enzyme replacement therapy refers to a medical treatment that involves administering synthetic or bioengineered enzymes to patients with enzyme deficiency disorders to restore normal metabolic function. For instance, in November 2023, Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company announced ADZYNMA, a recombinant ADAMTS13 enzyme replacement therapy approved by the U.S. Food and Drug Administration (FDA), a US-based government agency. This is the first and only treatment for congenital thrombotic thrombocytopenic purpura (cTTP) in both adult and pediatric patients. Congenital thrombotic thrombocytopenic purpura (cTTP) is an ultra-rare blood clotting disorder caused by a deficiency in the ADAMTS13 enzyme. Clinical trials supporting the approval demonstrated that ADZYNMA effectively reduced the risk of acute TTP events, and it is now available in the U.S. for both prophylactic and on-demand treatment.

Regional Outlook

North America was the largest region in the thrombotic thrombocytopenic purpura (TTP) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Thrombotic Thrombocytopenic Purpura (TTP) Market?

The thrombotic thrombocytopenic purpura (TTP) market consists of revenues earned by entities by providing services such as diagnostic services, immunosuppressive therapy, hospitalization & intensive care services, patient support programs, long-term management and follow-up care. The market value includes the value of related goods sold by the service provider or included within the service offering. The thrombotic thrombocytopenic purpura (TTP) market also includes sales of immunosuppressants, plasma-based therapies, monoclonal antibodies, and supportive care treatments. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Thrombotic Thrombocytopenic Purpura (TTP) Market Report 2026?

The thrombotic thrombocytopenic purpura (ttp) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the thrombotic thrombocytopenic purpura (ttp) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.